
Immuneering Corp (IMRX) Stock Forecast & Price Target
Immuneering Corp (IMRX) Analyst Ratings
Bulls say
Immuneering Corp demonstrates a positive outlook due to significant improvements in overall survival (OS) and progression-free survival (PFS) rates over current standard of care (SoC), which positions the company favorably in the competitive biopharmaceutical landscape. Furthermore, the safety data recorded shows enhancements in tolerability for atebimetinib compared to existing therapies and therapies in development, supporting the notion of a strong efficacy-tolerability balance. Lastly, the evidence of superior safety with potentially lower median PFS compared to another treatment option reinforces the therapeutic potential of Immuneering's offerings and enhances investor confidence in the company's future.
Bears say
Immuneering Corp faces a negative outlook primarily due to the higher rates of anemia observed in its studies, which could raise concerns about the safety and efficacy of its drug candidates. The implications of these adverse effects may hinder the company’s progress in clinical trials, potentially affecting future product approvals and market potential. Furthermore, the recurring mention of anemia raises red flags regarding the overall risk profile of Immuneering’s therapies, which could adversely impact investor confidence and valuations.
This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.
Immuneering Corp (IMRX) Analyst Forecast & Price Prediction
Start investing in Immuneering Corp (IMRX)
Order type
Buy in
Order amount
Est. shares
0 shares